TJC0316
TJC0316 belongs to a series compounds of second-generation autotaxin inhibitors used for IPF/NASH therapy, which are currently at the stage of lead optimizations. Many tests of PK and animal efficacy are under process. As such, they are in early discovery stage for drug development.